ClinicalTrials.gg
Drug

Gemcitabine-Releasing Intravesical System clinical trials

Also written TAR-200 and JNJ-17000139.

studies test it
8
open now
0
in phase 3
3
first study started
2016

How each study uses Gemcitabine-Releasing Intravesical System is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
3
Gemcitabine-Releasing Intravesical System
1

Development codes

TAR-200
5
JNJ-17000139
4

Studies by the year they started

8 studies that test it; most in 2016 (2)

Studies that test Gemcitabine-Releasing Intravesical System, by start year
YearStudies
20162
20171
20191
20202
20231
20241

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
1
Phase 3
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 8 · Other 0

Janssen Research & Development, LLC (5) · Taris Biomedical LLC (3)

Often tested with

Tested in the same studies.

Cetrelimab (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1, 1 in phase 3

Studies that test Gemcitabine-Releasing Intravesical System, phase 3 first.

Studies

Open first, then newest update. How each study uses Gemcitabine-Releasing Intravesical System is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 8

Given beside what is tested · 1 — Gemcitabine-Releasing Intravesical System is usual care or a partner of the new treatment